Skip to main content
. 2020 Mar 17;122(9):1399–1408. doi: 10.1038/s41416-020-0793-y

Table 2.

Clinicopathologic correlation of HLA-I expression type accordign to the tumour location.

Centre of tumour Invasive margin
HLA-I preserved HLA-I total loss Total P value HLA-I preserved HLA-I total loss Total P value
Age
  <65 51 (53.1%) 45 (46.9%) 96 0.377 60 (62.5%) 36 (37.5%) 96 1.000
  ≥65 110 (55.8%) 87 (44.2%) 197 123 (62.4%) 74 (37.6%) 197
Sex
  Male 99 (55.0%) 81 (45.0%) 180 0.539 114 (63.3%) 66 (36.7%) 180 0.711
  Female 62 (54.9%) 51 (45.1%) 113 69 (61.1%) 44 (38.9%) 113
pT stage
  pT1 80 (56.7%) 61 (43.3%) 141 0.317 95 (67.4%) 46 (32.6%) 141 0.116
  pT2–4 81 (53.3%) 71 (46.7%) 152 88 (57.9%) 64 (42.1%) 152
pN stage
  pN0 99 (55.6%) 79 (44.4%) 178 0.434 115 (64.6%) 63 (35.4%) 178 0.388
  pN1–3 62 (53.9%) 53 (46.1%) 115 68 (59.1%) 47 (40.9%) 115
Distant metastasis
 Absent 158 (44.8%) 128 (55.3%) 286 0.392 178 (62.2%) 108 (37.8%) 286 0.715
 Present 4 (57.1%) 3 (42.9%) 7 5 (71.4%) 2 7
CD3+ TIL density
  Low 67 (45.6%) 80 (54.4%) 147 0.001 71 (48.3%) 76 (51.7%) 147 <0.001
  High 94 (64.4%) 52 (35.6%) 146 112 (76.7%) 34 (23.3%) 146
CD8+ TIL density
  Low 71 (48.6%) 75 (51.4%) 146 0.002 80 (54.4%) 67 (45.6%) 147 0.005
  High 90 (61.2%) 57 (38.8%) 147 103 (70.5%) 43 (29.5%) 146
PD-L1 CPS
  Negative 65 (50.4%) 64 (49.6%) 129 0.101 77 (57.9%) 56 (42.1%) 133 0.089
  Positive 96 (58.5%) 68 (41.5%) 164 106 (66.3%) 54 (33.8%) 160
PD-L1 TPS
  Negative 103 (52.3%) 94 (47.7%) 197 0.117 118 (57.0%) 89 (43.0%) 207 0.002
  Positive 58 (60.4%) 38 (39.6%) 96 65 (75.6%) 21 (24.4%) 86
Total 161 132 293 183 110 293

Bold values indicate statistical significance P < 0.05.